TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07276282: Effects of Ziltivekimab Versus Placebo on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction. A Serial, Multivessel, Intravascular Ultrasound, Near-infrared Spectroscopy and Optical Coherence Tomograph

Sponsor: ECRI bv · Phase: PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 332 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$23,401,600

Rescue Site Savings

+$15,430,430

Unlock Full NCT07276282 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07276282 Rescue Dossier →